CalmiGo

Biofourmis raises $100M to scale digital therapeutics

Latest articles

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Product review: Bearaby weighted blanket

Bearaby weighted blankets are on a mission to provide you with deep sleep, peace of mind and a joyful feeling.   GO LONG    GO SHORT ...

Aging well: the new human imperative

Prof Andrew Scott touts the importance of compressing morbidity and aging well to realise multi-trillion dollar benefit of increasing life expectancy. Earlier this year, we...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
Seno

Editor's picks

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Product review: Bearaby weighted blanket

Bearaby weighted blankets are on a mission to provide you with deep sleep, peace of mind and a joyful feeling.   GO LONG    GO SHORT ...
CalmiGo

Click the globe for translations.

Health start-up Biofourmis, which leverages AI for personalised healthcare monitoring, has raised $100m from SoftBank.

SoftBank Group has led a $100m investment in Biofourmis, the health software start-up which uses AI to deliver personalised healthcare. Financing came from Vision Fund 2 and existing investors EDBI of Singapore, MassMutual Ventures, Openspace Ventures and Sequoia Capital also joined the Series C round [1].

Longevity.Technology: This further investment will allow Biofourmis to further develop its vision of moving “beyond the pill”. The company’s digital therapeutics solution will embed as a companion therapeutic to drugs, making an efficient model that will better treat and manage patients with complex chronic conditions, improving outcomes and reducing healthcare burdens. The new cash will also enable Biofourmis develop its portfolio, which includes digital therapeutics for pain and cancer.

Biofourmis’ wearable tech predicts problems for people with heart conditions and can raise the alarm about impending heart attacks days before they strike. It raised $35 million in its Series B round in May last year and in March, as the pandemic began its stranglehold on the world, Biofourmis were ahead of the curve. Deploying hundreds of wearable sensors that detected the early symptoms of COVID-19 to people in Hong Kong, the company was able to leverage its cloud-based health tracking platform to try to halt the spread of the virus.

The Biovitals® platform collects and interprets vast amounts of population metadata and compares it to real-time patient physiological signals to provide a clearer picture of chronic patients and their disease trajectory. Source: Biofourmis

 

Six months later, although C19 is still a global problem, more than 100,000 C19 patients have used the Biofourmis system. The Biofourmis platform includes an armband sensor manufactured by Biovotion (a company which Biofourmis acquired last year) which is paired with a smartphone app for patients. The platform continually analyses the patient’s biomarkers, communicating signals to the patient’s doctor via an online dashboard.

Biofourmis CEO Kuldeep Singh Rajput (pictured) said: “COVID-19 is pushing remote monitoring and digital therapeutics to the forefront of medicine. Our vision is to use digital medicine to empower patients, clinicians and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy.

“With this new funding, we will accelerate our global expansion, advance our digital therapeutics pipeline, develop additional care pathways and drive deeper integration with our health system, hospital, pharmaceutical and clinical research clients and partners [2].”

[1] https://prn.to/2QSSbgs
[2] https://bit.ly/2Fa73Vi

Image credit: Biofourmis
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
CalmiGo

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Seno

Related articles

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Digitalising healthcare for aging-in-place

PCL Health is expanding its digital footprint with wearables designed to increase and improve remote health monitoring for aging-in-place solutions. DISCLOSURE: Longevity.Technology (a brand of...

Crypto airdrop swells SENS coffers by $20m – and climbing

Pulse chain airdrop to support longevity research is live – and the numbers are staggering – four times annual budget in just two days. Cryptocurrency...

Crypto auction raises over $5m for longevity research

VitaDAO raises 400% of expectation and will use it to fund longevity research and projects that promote healthspan and lifespan. The world’s first decentralised intellectual...
Seno